| Party congress clearly the overall objective of health | | | | dimension C, penicillin and other "two high and one |
| system reform, medical residents will spur substantial | | | | capital" products, especially about the implementation |
| growth in consumer demand for our pharmaceutical | | | | of the "pharmaceutical industrial pollution emission |
| industry to create a good environment | | | | standards", will increase the bulk API business |
| unprecedented. In 2007, the State has published a | | | | environmental costs, water, coal, electricity, oil prices, |
| series designed to help the pharmaceutical industry, | | | | and labor, safety and other laws, regulations and |
| scientific and technological progress of related policies, | | | | standards of strict enforcement, would greatly |
| coupled with the various ministries should continue to | | | | increase the production of integrated cost, combined |
| introduce specific measures, from a technical, | | | | with the State Drug Administration Department is |
| regulatory levels to promote the system, which will | | | | preparing to introduce the export of drugs import |
| push forward the Chinese enterprises to improve | | | | and export of medical equipment management |
| their core competitiveness, further accelerate the | | | | practices and management measures on import and |
| pace of the world. In 2008, China's Foreign Trade | | | | export of growing efforts to standardize market |
| Medicines & Health Products will maintain rapid | | | | order, etc., will result in some weak or do not have |
| growth, chemical raw continue to be China's exports | | | | the business qualifications of the enterprises have |
| of medicine and health products industry mainstay, | | | | been eliminated, the majority of pharmaceutical |
| our conventional bulk chemical raw edge will be | | | | companies in the new regulatory environment policy |
| maintained, especially antibiotics, vitamins , hormone, | | | | experience a wider reshuffle. Determination and |
| antipyretic and analgesic, amino acids, alkaloids and | | | | innovation, targeting high-end products and markets, |
| other products will take up a considerable share in | | | | creating higher added value will undoubtedly be the |
| the world. With the domestic enterprises to improve | | | | first choice of new business wins, the extensive |
| productivity and technology, the export of Western | | | | growth mode of foreign trade is expected due to |
| medicines will speed up. Small and medium sized | | | | the adjustment within the industry and the |
| medical device while maintaining comparative | | | | emergence of new changes. |
| advantage and export competitiveness, while some | | | | (B) of the Chinese enterprises to seize the new |
| high-tech medical equipment products and high | | | | opportunity to speed up the pace of opening up the |
| value-added exports to grow steadily, our medical | | | | international market |
| equipment in the international market competitiveness | | | | 2008 for the year for large pharmaceutical companies |
| will gradually increase. In addition, China's TCM exports | | | | are full of business opportunities in China a year, the |
| will maintain the momentum of rapid growth, Chinese | | | | global pharmaceutical market will achieve 5-6% |
| crude drugs, extracts and health care products will | | | | growth, market size is expected to reach 735 000 |
| also achieve rapid export growth. 2008 is expected | | | | 000 000 -7.45 thousand billion dollars, the world will |
| to medicine and health products in China is expected | | | | have annual sales About 200 million worth of drugs |
| to maintain more than 20% increase in total imports | | | | facing patent expiration, is equivalent to the previous |
| and exports to more than 40 billion U.S. dollars. In | | | | two years combined. Which, Risperdal, Fosamax, |
| general, in 2008, China's pharmaceutical import and | | | | Topomax, Lamictal and Depakote and other products |
| export situation would seem to present the following | | | | will be more mainstream end of the world market |
| new features: | | | | exclusivity, which will drive generics market to grow |
| (A) of the new industrial policy factors, medical | | | | at 14-15%, reaching 700 billion. 2008, the United |
| foreign trade structure, China will have a major | | | | States more than two thirds of prescription drugs will |
| impact | | | | be generic. Germany's new government contracts |
| Long time, the pharmaceutical industry has been | | | | implementation plan as well as Japan, Spain and Italy, |
| influenced by the government's policy of one of the | | | | the educational project to promote generics in the |
| industries, and since the beginning of 2007, for the | | | | market more widely used. In addition, |
| pharmaceutical industry's policies and measures as | | | | GlaxoSmithKline, AstraZeneca and other multinational |
| much as, density and impact of the deep is rare over | | | | companies have begun to shift their production bases |
| the years, these policy factors bound to the | | | | to China, many multinational companies in China has |
| continuation in 2008 and highlights the significant | | | | been and will continue to establish more research and |
| policy effects. Among them, the newly-introduced | | | | development center. In the global pharmaceutical |
| "Drug Registration" will encourage powerful | | | | manufacturing hub to Asia, led the trend, China will |
| enterprises, especially enterprises increase | | | | have more and more enterprises patent expiration |
| independent R & D, improve innovation, more | | | | generic products carry more bulk drugs, formulations |
| companies from tapping the potential development of | | | | and other products of international production, R |
| the internal power source or through foreign technical | | | | & D outsourcing, commissioned to carry out |
| cooperation to find new breakthrough. State | | | | drugs clinical trials, more extensive participation in |
| promulgated the "Guiding Catalogue Industrial | | | | international division of labor and cooperation even |
| Restructuring (2007 version)," to limit the production | | | | more refined. |